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ambiguous genitaliainvolvement of a tertiary centre for assessment and management
recommendations. This article describes the structure of the
multidisciplinary team (MDT) at our centre, with contributions
from key members of the team regarding their individual roles.
The focus is on the newborn referred for assessment of ambiguous
genitalia, rather than on individuals who present in the adolescent
period or at other times, although the same MDT involvement is
likely to be required. The approach to the initial assessment and
management is discussed and the subsequent diagnosis and
follow-up presented, with emphasis on the importance of careful
transition and long-term support.
 2010 Elsevier Ltd. Open access under CC BY license. The management of a newborn or newly presenting adolescent with a disorder of sex development
(DSD) can be a difﬁcult challenge for health-care professionals and one which requires a holistic
approach from the outset.
The primary aim should be to achieve a diagnosis, sex assignment (if needed) andmanagement plan
as quickly as possible, but without rash decisions being made. Thus, early liaison and assessment by an
experienced multidisciplinary team (MDT, or interdisciplinary team) is essential.1,2
Ideally, the MDT would be composed of an endocrinologist, urologist, gynaecologist, psychologist,
biochemist and clinical/molecular geneticists, with access to ethical advice and with supporting
specialist pathology and imaging where needed (Fig. 1). However, DSD can present to many different
health-care professionals and at different ages (Table 1). Therefore, an awareness of these potential
diagnoses, appropriate terminology and the need to involve specialist services early is required by all
practitioners dealing with children and young people.3–5
In this article, we outline our experience from the MDT at Great Ormond Street Hospital and detail
the various specialists’ input to the overall service. Transition is made to the Adolescent MDT at
University College London Hospitals (UCLH), which comprises a similar spectrum of professionals.
Thereafter, there is a ﬁnal transition to the MDT adult DSD service, also at UCLH. Of course, the exact
composition of the team may vary from one centre to another and not all the resources described are
always available within our setting.
Presentation of DSD
As noted above, DSD can present to many different health-care professionals and at several
different ages (Table 1). Whilst the majority of infants with DSD present with genital ambiguity at or
shortly after birth, an increasing number of individuals are identiﬁed either antenatally or during
childhood and adolescence. Adults diagnosed with DSD will sometimes present through infertility
clinics.Antenatal
The relatively frequent practice of chorionic villus sampling or amniocentesis for trisomy screening
in some countries may identify a mosaic karyotype (e.g., 45,X/46,XY), or the phenotypic sex of the baby
on ultrasound or at birth may be found to be discordant with the karyotype (e.g., complete androgen
insensitivity syndrome, CAIS). When karyotype–phenotype discordance is present, appropriate
education and counselling can be provided to the parents so they are aware of the likely investigations
and decisions that may be necessary at birth. In the future, focussed trisomy screening or earlier non-
invasive testingmay reduce the frequency of this presentation but, by contrast, non-invasive foetal ‘sex
determination’ will become easier.6 Of some concern is the practice of sexing the foetus during routine
antenatal ultrasound scans. This has led to some very difﬁcult situations, particularly when the baby is
born unexpectedly with genitalia that are ambiguous or are discordant with the parents’ expectations.
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Fig. 1. An overview of the multidisciplinary team.
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Genital ambiguity is the most frequent presentation of DSD in the newborn period. However, it is
sometimes masked by local swelling (breech presentation) or may be apparent (e.g., clitoral hyper-
trophy in the premature infant with little suprapubic fat). The empty scrotum of a genetic (46,XX)
female with a severe virilising form of congenital adrenal hyperplasia (CAH) is something which, if
missed on the postnatal inspection, can have signiﬁcant consequences such as adrenal crisis or
incorrect sex of rearing.
Bilateral undescended testes should always be referred for further assessment as should the
presence of inguinal herniae. Hypospadias occurs in approximately 1:250 newborn boys and will
usually be referred to a paediatric urologist. In some cases, more detailed investigationwill be required,
especially if the form of hypospadias is severe (e.g., penoscrotal) or associated with a small penis with
poor corporal consistency and/or undescended testes.
Childhood and adolescence
Some conditions may present with androgenisation during childhood (e.g., 11b-hydroxylase deﬁ-
ciency) or at adolescence (e.g., 17b-hydroxysteroid dehydrogenase deﬁciency type 3; 5a-reductase
Table 1
An overview of different presentations associated with DSD at different ages.
Presentation Prenatal Birth Infant Child Adolescent Adult
Prevalent
Ambiguous genitalia (þ) þ (þ)
Amenorrhea (þ/ pubertal development) þ
Less prevalent
Karyotype/phenotype discordance þ þ
Bilateral undescended testes þ þ
Hypospadias/small penis (þ) þ þ þ
Adrenal failure þ þ þ
Inguinal herniae in a girl þ þ þ
Premature sex development þ þ
Hypertension þ þ þ þ
Other features (e.g. ﬁts, Wilms’ tumor) þ þ þ þ
Androgenization in puberty þ
Gonadal tumour (þ) þ þ
Infertility (þ) þ
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of some other forms of DSD (e.g., 17a-hydroxylase deﬁciency, CAIS or gonadal dysgenesis).
Initial approach to the newborn with DSD
This section focusses on the newborn with genital ambiguity, as this is a relative emergency that
requires prompt and efﬁcient communication between the referring hospital and the tertiary centre.
Management at birth
It is of vital importance that all professionals involved with the management of the newbornwithin
the labour ward and on the postnatal wards are knowledgeable about what to do when a baby is born
with indeterminate sex. If in any doubt, the sex of a baby should never be guessed. A senior paedia-
trician should counsel the parents in the ﬁrst instance, and a clear plan of further management out-
lined. A prompt referral to a specialist centre should then be made.
Often, a child with ambiguous genitalia is born at a local hospital, so initial specialist management is
at a distance. The presence of ambiguous genitalia is not amedical emergency in itself, so parent–infant
interaction is essential and the child should not be unduly ‘medicalised’. However, the adrenal
insufﬁciency associated with some forms of DSD can become an emergency if overlooked and not
treated early, so vigilance (e.g., hypoglycaemia) and monitoring (e.g., electrolytes) are necessary until
adrenal dysfunction is excluded and the karyotype is known. Steroid and salt replacement treatment
will be needed if adrenal insufﬁciency is suspected.7
Information should be given to the family in a consistent manner that is appropriate for their level
of understanding, with awareness of religious and cultural beliefs and preconceptions (e.g., their
desire for a speciﬁc family structure or information about the foetal sex given from prenatal scans).8
Parents often experience extreme stress about the disclosure of the problem to family and friends
and ﬁnd uncertainty very unsettling. This issue is compounded if they have already told relatives
about the expected sex, or have prepared the baby’s room or bought clothes accordingly. Indeed,
many neonatal nurseries focus on ‘pink’ or ‘blue’, so even the hospital environment can be extremely
challenging.
In addition to the endocrine issues, it is essential to appropriately address social, psychological and
urological aspects of management in the early period, and early contact with the MDT can give reas-
surance to the family whilst also focussing on the appropriate investigations needed to make a diag-
nosis and in some cases to establish the appropriate sex assignment.
Sending the appropriate samples for rapid karyotype analysis by ﬂuorescence in situ hybridisation
(FISH) or quantitative ﬂuorescence polymerase chain reaction (QFPCR), and discussing the issues with
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category can be reached quickly (see the article on classiﬁcation this issue).1–3
Initial specialist assessment
Once the referral to the specialist MDT has been made, the initial assessment of the baby is planned
on an individual basis, but based on a standard structure of investigations and assessments9 (UKDSD
Taskforce Guidelines in preparation). Investigating cases of karyotype–phenotype discordance involves
a similar approach to that for the newborn with ambiguous genitalia, but the parents are usually more
aware of the potential issues if they have been counselled antenatally. Great care must be taken not to
instil any preconceptions as to the sex of rearing until the baby has been assessed after birth, as this can
result in inappropriate decisions being made with challenging long-term consequences.
If the sex of rearing is unclear, the family will be referred to the specialist centre within a few days.
An emergency slot is available where the on-call urologist, endocrinologist and, often, clinical
psychologist will assess the baby. Therewill be a keymember of each teamwhowill communicatewith
individual families, establishing a rapport, ensuring consistent information is given and acting as
a point of contact.
It may not be possible to decide on the appropriate sex of rearing at the ﬁrst meeting as this may
depend on the results of biochemical investigations and sometimes also on endoscopic assessment.
Most importantly, however, the family should feel supported, and strategies for coping with the
uncertainty of gender assignment will be discussed with them. In particular, advice as to how best to
impart information to family and friends will be given, which helps to alleviate some of the stress that
the family inevitably feels that they are under.
Additional investigations
An indicator of karyotype, such as rapid FISH analysis, will usually be known by the time of the ﬁrst
meeting, and this together with the genital appearances will guide the subsequent assessment.
The exclusion of any associated adrenal insufﬁciency is of paramount importance and will be made
in almost every case in our centre. A urinary steroid proﬁle ideally forms part of the routine assessment
in many cases, as this will not only help with adrenal insufﬁciency, but will also provide diagnostic
information after the third day of life in most forms of CAH, and from 2–3 months for 5a-reductase
deﬁciency.
Whether to stimulate potential testicular tissue with a 3-day or 3-week human chorionic gonad-
otropin (hCG) stimulation test can be a difﬁcult decision, especially if a female sex of rearing is being
considered. The effects of postnatal androgen exposure to the developing brain are unknown, espe-
cially if the baby is subsequently raised female. Measurements of anti-Mu¨llerian hormone and inhibin
B are proving increasingly useful for assessing gonadal (testicular) integrity, but these assays are not
established in all centres and results are not always available quickly if assays are run intermittently or
if samples are sent out to specialised centres for analysis.
Genital photography will often be undertaken at the ﬁrst meeting and again after any gonadal
stimulation. However, detailed notes of the genital examination should be made by the urologist as
photographs can be misleading (e.g., suprapubic fat pad) and corporal consistency on palpation is not
always reﬂected well by images. Any potential dysmorphic or associated features should be noted and
the experience of a clinical geneticist obtained early in such situations, as such signs can be subtle in
the early newborn period.
Imaging (e.g., pelvic ultrasound) has a role in locating gonads and possibly identifying Mu¨llerian
structures but should be viewed with extreme caution, especially if undertaken by an inexperienced
radiologist. This can be misleading, even in experienced hands. The presence of Mu¨llerian structures or
descended gonads by themselves should not be the deciding factor in gender assignment, but parents
often focus on this information, especially if the limitations of this analysis are not explained.
The aims of the initial assessment and subsequent presentation at the MDT are to establish the
appropriate sex of rearing, form a plan of diagnostic procedures and provide psychological support for
each individual family as a whole. Several factors need to be considered when counselling the family
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for endocrine replacement; fertility options and long-term tumour risk. These factors can be inﬂuenced
by the underlying diagnosis; therefore, attempts at achieving a speciﬁc diagnosis as soon as possible
are important. However, it is also extremely important that every case is viewed individually, as the
range of phenotypes can vary signiﬁcantly even within patients with the same underlying diagnosis,
and long-term outcome data for many forms of DSD are not readily available.10
Of course, it is of vital importance that parents are involved in the decision-making process and are
fully aware of the potential implications for the child. To have to contemplate gender reassignment at
a later stage is one of themost difﬁcult areas and can take several lengthy consultations between family
and professionals. Adopting an MDT approach can help facilitate parents’ understanding of the issues,
and provides continuity of care and consistency of information. Clear communication between
members of the MDT is therefore essential.
The multidisciplinary team
As recommended in the ‘consensus statement’, children with DSD should be managed by an MDT
with appropriate expertise and experience in managing these conditions.1,2 The exact composition of
the team will vary from one centre to the next, but some of the key team members and related
disciplines are shown in Fig. 1. Not every professional will be relevant to each individual patient, but it
is important that they have the opportunity to express an opinion and provide suggestions.
An endocrinologist’s view
The endocrinologist plays a key role in coordinating investigations and management, and is usually
the ﬁrst point of contact for referral. All endocrinology consultants in our centre are well experienced
in the range of disorders that can present with ambiguous or discordant genitalia and are appropriately
placed to deal with essential aspects of monitoring (e.g., electrolytes); obtaining and interpreting ﬁrst-
line investigations (e.g., basal and stimulated steroid tests and urine steroid analysis); and coordinating
steroid replacement therapy (e.g., glucocorticoids, mineralocorticoids and salt), where necessary. The
fact that adrenal disorders associated with DSD are common and are a medical emergency if not
recognised and treated appropriately means that the endocrine team is central to the initial stages of
assessment and management. The endocrinologist can also advise about the likely need for endocrine
replacement at puberty and, in adulthood, explain and monitor growth and fertility issues, and often
has awareness of related medical issues in complex or multisystem cases (e.g., cardiac or renal
anomalies). Adolescent endocrinologists play a key role in the induction of puberty, if needed, and
adult endocrinologists with working experience of long-term administration and monitoring of
hormone replacement therapies are essential for continuing long-term support as appropriate.
A urologist/surgeon’s view
The surgeon (paediatric surgeon or paediatric urologist) will always be a key member of the MDT,
and may be the ﬁrst point of referral, especially in those centres without an established MDT.
In specialist centres, the initial evaluation of the child with DSD should be performed in a joint
manner by the surgeon and endocrinologist. Ideally, both of these individuals will have expertise in the
management of such babies. The assessment will include a detailed history, identifying any points of
relevance (family history, antenatal history and so on). The surgeon will need to carry out a detailed
examination of the genitalia, focussing upon the presence and location of the gonads, the size and
appearance of the phallus, the number and location of the urethral/vaginal oriﬁces and the appearance
of the labioscrotal folds and to conﬁrm a normal situation of the anus. The ﬁndings of the examination
should be discussed with the parents in a manner concordant with their level of understanding. In
general terms, one should avoid the use of terminology that would favour one sex over another. For
instance, using the term gonad rather than testis/ovary or phallus rather than penis/clitoris would be
advised. Some parents may not be familiar with such medical terms and this would need to be
ascertained from them at an early stage in the consultation.
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a boy or a girl). Generally, the surgeon and endocrinologist can form an opinion about the appropriate
sex of rearing at the initial consultation, particularly if preliminary investigations have already been
carried out. Where uncertainty exists, a decision about sex of rearing should be deferred until inves-
tigation results are available and the MDT has been involved in the decision-making process. In such
cases, detailed discussions about a possible sex of rearing and potential surgery required are best
avoided at the initial meeting. Information should be given to the parents in a graded manner, to allow
time for reﬂection and assimilation. This process may take a number of meetings with various
members of theMDT, but key individuals such as the surgeon, endocrinologist and psychologist should
always be present to maintain continuity. Often, parents will come with a body of knowledge ascer-
tained from the referring centre or the Internet. In such instances, this information needs respectful
consideration and clariﬁcation where incorrect or misleading information has been gained.
The surgeonwill use the initial evaluation to start to build an image of the genitalia at presentation,
consider if changes may occur in the early months of life and to determine what investigations are
likely to be needed to helpmake the diagnosis and guide decisions about the sex of rearing (cystoscopy,
vaginoscopy, laparoscopy and so on). Finally, the surgeonmaywant to consider the nature and number
of surgical procedures that may be required to achieve a desired outcome and if the involvement of
other surgical specialists (e.g., gynaecologist) is likely to be needed.
Ultimately, it is the surgeon’s responsibility to undertake surgery for genital ambiguity if considered
necessary, to restore function and achieve an acceptable cosmetic outcome. There are instances where
surgery may not be required or desired by the parents or where surgery is best delayed until
adolescence or adulthood. The latter approach is becoming increasingly popular and the effect of this
paradigm shift will only become apparent in the future. Careful long-term follow-up is therefore of
paramount importance.
Children raised male are likely to require at least two surgical procedures to reconstruct the penis in
the ﬁrst 2–3 years of life. In the majority of cases, the cosmetic and functional outcome is very good. In
others where the penis is particularly small, a good outcome in terms of size may not be achievable.
Some children raised male may require orchidopexy, or even gonadectomy where streak gonads are
present. Mu¨llerian structures of a signiﬁcant size may also require removal, whilst smaller Mu¨llerian
remnants can be left in situ as usually they do not cause signiﬁcant problems.
Children raised female may or may not require surgery in early childhood. Minor degrees of clitoral
enlargement do not require surgical reduction and even when clitoral enlargement is signiﬁcant,
reduction surgery should only be carried out after the parents have been counselled about the
advantages and risks of such a surgery. These discussions would require the involvement of a paedi-
atric/adolescent gynaecologist from an early stage. In some children, the surgeon may recommend
a vaginoplasty in the ﬁrst 1–2 years of life, and indeed this is currently the standard practice in girls
with a long urogenital sinus. This does not, however, obviate the need for further surgery in adoles-
cence or early adulthood and parents should be made aware of this. It is entirely reasonable for those
children with a relatively short urogenital sinus to have surgery deferred until adolescence or early
adult life, thereby enabling the individual to be involved in the decision-making process.
Finally, the surgeon may be required to surgically remove gonads to protect the individual from
gonadal malignancy. The timing of such surgery depends upon the nature of the DSD and the relative
reported risk of malignancy.1,11 Decisions of an irreversible nature should be evidence based asmuch as
possible and made in conjunction with the MDT.
A gynaecologist’s view
The role of the gynaecologist in the clinical management of a neonate or infant with a DSD is initially
advisory only. A gynaecologist is not usually involved in the practical care of the small child but can
offer information on long-term aspects such as sexual function and fertility. Parents may ﬁnd it useful
to meet and discuss potential adolescent and adult issues prior to taking a decision about genital
surgery.
However, it is essential that a gynaecologist is involved in the care of children with a known DSD as
they approach puberty and also in the care of newly diagnosed adolescent patients. Patients with
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menstruation. This is usually performed under a brief general anaesthetic. If vaginal stenosis is present,
then surgical reconstruction may be required. The examination may need to be repeated later in
adolescence to ensure the vagina is adequate for both tampon use and sexual intercourse.
In those girls where the uterus is absent, vaginal examination can be deferred until later in
adolescence and does not usually require an anaesthetic. If the vagina is short, vaginal dilation treat-
ment is the treatment of choice and is successful in about 85% of patients.12 Thosewho are unsuccessful
will require surgical reconstruction with a variety of methods such as the laparoscopic Vecchietti
procedure or intestinal vaginoplasty, depending on the diagnosis and prior surgical intervention.
A psychologist’s view
The physical and psychological health needs for individuals with a DSD are closely interrelated.
Medical management decisions in DSD are often based on promoting psychological adaptation and
well-being rather than a physical health need per se. Even for individuals where decisions are made on
the basis of physical considerations, the possible impact on psychological well-being needs to be taken
into account. It is therefore essential for psychological well-being and adaptation to be seen as
inseparable frommedical management and for this reason psychological support and intervention are
most effectively provided as an integral part of MDT care. The importance of a psychologist, or similar
professional, in themanagement of DSD is not about pathologising DSD, but rather is recognition of the
exceptional personal and social challenges that a diagnosis of DSD presents.
Adequate psychological care requires highly specialist skills and knowledge and in general should
not be undertaken by local services in isolation from the MDT. The experience of working with indi-
viduals and families with DSD is essential to appreciate the complexity and sensitivity of the issues that
commonly arise. In addition, an understanding of sex development and experience of gender identity
development and factors inﬂuencing sex-role behaviour and sexuality together with knowledge of the
trajectory of a DSD across development are required.
Psychological input is best considered as a process and not an event and contact with psychology is
both routine, or pre-emptive, and reactive as issues arise. Planned episodes of medical care may not
coincide with an individual’s needs at particular points in time and, therefore, ideally the family and
affected individual will feel able to initiate contact as and when required.
Psychological support is not embodied in the psychologist alone; rather, the presence of
a psychologist in the team represents recognition of the interrelating physical and psychological
aspects of DSD, as well as being a resource for individuals and their families with a DSD. It has become
increasingly apparent that the way in which DSD is managed by health professionals affects psycho-
logical outcomes. Integrated holistic management has evolved in response to patient feedback and
outcome research that has shown the long-term psychological distress associated with – among other
things – surgery without consent, medical photography, repeated genital examinations, uncontained
disclosure or unhelpful phrasing of sensitive information.13
Well-integrated MDTs provide scope for roles to develop based on the individual skills of the team
members. Whilst there are tasks that clearly require the particular skills of a psychologist, other roles
may emerge. In practice, the psychologist is often in a good position to act as an advocate and point of
contact for families and individuals with a DSD and coordinate contact with other members of the
team. Teamwork and close communication between teammembers facilitate the appropriate timing of
medical interventions based on the needs of the young person; for example, when information needs
to be given to a young person before the introduction of sex hormones at puberty or in cases where
a decision needs to be made in puberty about gender identity. In this case, a gonadotrophin-releasing
hormone (GnRH) agonist may be used to suppress puberty and to provide time and space for the
psychologist to work with the young person and their family to reach a decision prior to any surgical
intervention.
As an optimum, contact with psychology is initiated at the time of ﬁrst contact with the team and, as
with all members of the team, a collaborative, trusting relationship that respects and acknowledges
individual, cultural, social and personal circumstances is actively fostered. Whilst the care of the
individual with a DSD is central and foremost, important decisions are often taken on their behalf early
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encompass the family unit. There are crucial times when psychology has a role to play in relation to
both medical management and individual development, including decisions about sex of rearing,
surgical intervention, introduction of sex hormones, information about diagnosis and decisions about
sex re-assignment, as well as routine support and monitoring of social and emotional well-being. In
addition, psychological input should be available for unforeseen issues, including, for example, parental
or individual concerns about gender identity development, school-related problems and bullying.
There are speciﬁc tasks at different stages of development, which should be planned with families
from an early stage. In particular, families may require considerable support from the MDT to feel
conﬁdent to give information to their child about their diagnosis and personal history in relation to this
condition. The pacing and timing of giving information and making decisions is ideally based on
individual circumstances, together with information about the DSD. Whilst decisions should be
informed by evidence when possible, most often there is no ‘right’ course of action that applies in all
circumstances. Rather there are broad goals, which are best approached with ﬂexibility on a case-by-
case basis. With this in mind, families and individuals require clear information about DSD and,
sometimes, intensive input to empower them to successfully address challenges as they arise.
Issues at birth
Uncertainty about sex of rearing creates considerable practical and emotional challenges for
parents. There is often an intense desire to move from uncertainty to certainty and a focus on medical
intervention with the hope that it will provide the solution. In cases where diagnostic tests and
physical examinations are not decisive in decisions regarding sex of rearing, it is particularly important
to involve the psychologist, whose role is to provide time and space for discussion. The process of sex
assignment is not only about making a decision but also an opportunity to process what has happened
and set out plans for the future. Traumatic memories of the birth, careless words by professionals,
misinformation from the Internet and unresolved fears about what will happen at puberty often
resonate and can cause considerable distress and damage when they re-emerge at a later stage.
Initial discussions most often cover practical issues such as what to tell family and friends and
a review of what the family has understood thus far with the aim of identifying fears and miscon-
ceptions. For families to make informed decisions, it is helpful to describe the process of sex deter-
mination and the implications of any decision into adult life, including puberty and fertility. In addition,
psychological factors, including the deﬁnitions and distinctions between gender identity, sex-role
behaviour and sexual orientation, together with known outcomes should be shared. Team meetings
with the family to address questions that arise in discussions with the psychologist regarding the DSD,
and possible medical interventions, are invaluable to maintain consistent information and prevent
confusion.
Information management
Facilitating disclosure of information about a DSD has emerged as a key role for psychologists in the
MDT. Commonly, parents do not feel they have the required knowledge to explain a DSD to their child
and fear that information may cause distress or precipitate a crisis. Therefore, early and ongoing
discussions with parents are required to address fears they may have about the impact of information
on their child and to plan what information might be given when. The diagnosis of a DSD in adoles-
cence presents particular challenges and is commonly associated with both the need to give infor-
mation and to make difﬁcult decisions about medical intervention or sex assignment.
Sex reassignment
There are particular circumstances that are exceedingly challenging both for the individual con-
cerned and their family. The issue of sex reassignment can present at various stages throughout life.
Typically, in a paediatric setting, the question can arise either shortly after birth, for example, when
a male-assigned baby is found to be a 46,XX infant with CAH, during childhood when parents or the
child express uncertainty about gender identity or at puberty when male-type secondary sexual
development occurs in a female. Invariably, the team psychologist will be asked to provide an
assessment. There are a number of standardised questionnaires available to aid assessment. Gender
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appropriately advise families. The implications of a change in gender need careful evaluation and
planning. For example, families commonly request a change of both school and location. Any change in
sex assignment after the age of about 12–18 months should only be considered if the child itself is fully
involved and initiates the discussion.
In conclusion, whilst certain aspects of the management of DSD clearly require input from
a psychologist or similar professional, their actual role in the MDT evolves with the team and it is this
dynamic integration of medical and psychological support that provides the best model of care.
A biochemist’s view
A number of biochemical tests will be needed in the diagnosis and management of a patient with
a DSD. A clinical scientist with an interest in DSD can advise the interdisciplinary team on the inter-
pretation of tests and ensure effective use of small biological samples. Knowledge of assay speciﬁcities
and reference ranges is important. A negative test result can be spotted and, through dialogue with the
clinicians, the next stage of investigations can be instigated through further test requests.
The priorities for hormone tests are different depending on the age of the patient and the clinical
problem. The assays needed are summarised in Table 2. In addition to steroid hormones and their
regulatory peptides (adrenocorticotropic hormone (ACTH), luteinising hormone (LH) and follicle
stimulating hormone (FSH)), assays for anti-Mu¨llerian hormone (AMH), Mu¨llerian inhibiting substance
(MIS) and inhibin B have become available to provide further information about testicular develop-
ment.14,15 Many laboratorieswill be able tomeet some of the requests by assays available internally, but
in many cases samples will be referred to specialist centres. Hormone assays are performed these days
usually on automated platforms using immunoassay with different detection systems such as chem-
iluminescence. These assays are not always the best tests for samples from young patients because of
the potential for interference from foetal and placental hormones. Many laboratories do not have the
appropriate paediatric reference ranges – an important example here is plasma testosterone
concentrations in genetic (46,XY) males that change with postnatal age in the ﬁrst year of life.
Testosterone concentrations up to 10 nmol l1 are seen at birth and from 3 weeks to 6 months of age,
but concentrations can be less than 1 nmol l1 at 1 week of age and from 6months of age until the start
of puberty.16 When testosterone production is naturally low, stimulation tests of the axis may be
needed. Plasma renin activity and aldosterone concentrations need to be known in some of the
conditions of DSD. Few laboratories have reference ranges in children but interpretation of the results
is dependent on knowledge of the normal levels. For some of the DSD conditions associated with
adrenal failure, there is a need for rapid turn-around times for hormone assays; DSD causes much
anxiety within the family and this should be borne in mind. The most common DSD in a 46,XX indi-
vidual is CAH due to 21-hydroxylase deﬁciency. The analysis of 17-hydroxyprogesterone (17-OHP)Table 2
Laboratory services for the initial investigation of DSD.
Plasma (essential) If ﬁrst plasma tests not
fully informative
Urine
46,XX DSD -
newborn
17-OHP, cortisol, androstenedione,
ACTH. Electrolytes.
Synacthen test.
In some cases will need plasma
renin activity (concentration)
and aldosterone concentration.
DHAS, 11-deoxycortisol Steroid proﬁle very effective
for adrenal disorders.
Characteristic patterns for defects
of CYP21A2, HSD3B2, CYP11B1, CYP17,
and POR. Very low levels of steroids
are seen with defects of CYP11A1and StAR.
46,XY DSD -
newborn
Plasma testosterone, DHAS,
LH, FSH. AMH, inhibin B
(ACTH, Synacthen test)*
Plasma androstenedione,
testosterone, DHT
(before and after hCG).
Steroid proﬁle can exclude 17-hydroxylase
and 3b-hydroxysteroid deﬁciencies
but not helpful for testicular defects
except 5a-reductase deﬁciency.
DHAS - dehydroepiandrosterone sulphate.
DHT - 5-alpha dihydrotestosterone.
* Consider tests of adrenal function in 46,XY DSD.
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a direct assay (antibody coated-tube, radioimmunoassay) not appropriate for paediatric investigations.
There are considerable interferences from foetal steroids in the ﬁrst few days of life, so most labora-
tories will not accept samples until the child is at least 3 days of age. Kits for 17-OHP usually have
a working range only to around 60 nmol l1. These methods are not targeted for the much higher
concentrations seen in classical CAH and are aimed at detection of heterozygotes and non-classic forms
of CAH. To get a better measure of the plasma 17-OHP concentration in an infant with classical CAH, it
will be necessary to use lesser amounts of sample. Ideally, steroid should be extracted into an organic
solvent before immunoassay to leave foetal zone-derived steroid sulphate in the sample matrix.17
Assays are available using extraction and mass spectrometric detection that are speciﬁc and accurate
from the ﬁrst day of life.18–20 Wherever possible, such assays should be used. An abnormal result for
one hormone should be treated with caution; the defect of cytochrome P450 oxidoreductase deﬁ-
ciency, for instance, affects the activity of two enzymes and corticosterone and progesterone should be
measured as well as 17-OHP.21
Many laboratories are now looking at mass spectrometric techniques for steroid assays and in the
next few years, an improvement in assay quality is anticipated.20,22 There is much variation in the
quality of these steroid assays because, in essence, the assays were developed ‘in-house’. There are in
use different standards, stable isotope-labelled internal standards, extraction techniques, chroma-
tography, ionisation and fragment focussing. Many laboratories have little experience of mass spec-
trometry. Problems are encountered from matrix interference and skill is needed to spot these
problems.23 Reference ranges will have to be established for children using new methods because
results are lower thanwith current, less speciﬁcmethods. The simultaneous analysis of several steroids
has been achieved in a few specialised laboratories.
If the plasma 17-OHP is normal, then other steroid measurements will be needed (Table 2). In view
of the range of diagnostic possibilities, a urinary steroid proﬁle is an extremely useful test of adrenal
function.24,25 Some of the plasma assays are not readily available (e.g., corticosterone). In general,
androgens from the adrenal cortex are produced in very much greater amounts than from the gonads
and abnormalities of testicular androgens are not apparent in the analysis of the metabolites in the
urine. A defect of 5-a reductase is an exception through analysis of 5a- and 5b-reduced steroid ratios of
androgens and cortisol metabolites. The urinary steroid proﬁle test uses gas chromatography (GC) to
separate the steroids in an extract of urine and the pattern over the time of the analysis indicates where
steroids are deﬁcient or produced in excess. The identiﬁcation of steroids is improved when the output
of the GC is a mass spectrometer. Each peak of steroid eluting from the GC has a characteristic
molecular weight and fragmentation pattern. All of the adrenal genetic enzyme disorders can be
identiﬁed in one analysis. A urine sample should, however, not be collected in the ﬁrst 3 days because
during that period of time there are many placental steroids in the urine of the child and clearance of
the metabolites of the substrates for defective enzymes is relatively lower than in later samples. The
laboratory needs experienced scientists to interpret the data and offer advice to clinicians. Detailed
reference ranges for age and gender are needed because of changes throughout childhood.
The adrenal enzyme DSD disorders are amenable to genetic analysis, either as a clinical service or on
a research basis.26 Other genetic analyses may be needed for androgen, LH and AMH receptors and
other genes involved in developmental pathways (e.g., steroidogenic factor-1), under the guidance of
clinical/molecular geneticists (see below).27
A clinical/molecular geneticist’s view
Clinical and molecular geneticists have several important roles to play as part of the DSD MDT.
Laboratory services are likely to be involved in the early stages of investigation by performing rapid
ﬂuorescence in-situ hydridisation (FISH) analysis of lymphocytes for the presence of X chromosomal
and Y chromosomal material (e.g., using a probe directed at SRY). Close liaison with the laboratory is
necessary, therefore, to inform them that this is an urgent rather than a routine sample, and to have the
results interpreted in light of the clinical ﬁndings (e.g., ambiguous genitalia). Results are usually
obtained within 48 h and provide a very important early component of the diagnostic pathway. A full
G-banded karyotype should be checked when available to conﬁrm initial ﬁndings and to ensure no
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centres, initial rapid ‘karyotype’ analysis is performed by QFPCR of DNA. In complex cases, array
comparative genomic hybridisation (CGH) or single-nucleotide polymorphism (SNP)/copy number
variant (CNV) analysis may also be performed looking for submicroscopic deletions or duplications that
might be relevant.
The clinical geneticist can provide valuable input for the diagnosis of many potential syndromic
associations of DSD and in assessing dysmorphic or variant phenotypic features.28 Such features may
be subtle, especially in the newborn. Reference to specialist literature, dysmorphology databases or
clinical genetics review meetings might be needed, especially for unusual collections of features. The
geneticist can also provide input into known single gene causes of DSD and can give guidance as to
where genetic testing might be available, either as a clinical service or as part of an approved research
protocol.29 Close interaction with academic laboratories may be necessary if detailed in vitro studies of
protein function need to be performed to understand the effects of any change in more detail.
Finally, clinical genetics has a very important role to play in counselling individuals and/or their
families about likely long-term aspects of speciﬁc conditions; inheritance patterns and the likelihood
of other familymembers being affected or be carriers; and the advantages and risks of prenatal analysis
and possible prenatal treatment options for conditions such as 21-hydroxylase deﬁciency. Professional
training and experience in counselling is important.
An ethicist’s view
Ethics is often described as a set of rules or principles that distinguish between right andwrong; it is
essentially about moral values rather then facts. When there appears to be no single obvious and
acceptable ‘right’ way to do something, ethics provides a means of evaluating and choosing between
different, often competing options.
Ethical conﬂicts arise when:
(1) application of clinical facts alone cannot determine what should be done;
(2) there is disagreement about the right course of action;
(3) application of moral principles conﬂict; and
(4) the law is ambivalent or silent.
Ethical conﬂicts require professionals to make value judgements to resolve them. Since individuals
within MDTs derive their own moral values from a wide range of sources, for example, family
upbringing, education, religious beliefs and professional codes, it may be difﬁcult for them to agree on
which set of values they should apply in individual cases. Ethical interventionmay provide clariﬁcation
in a way that is supportive, educational and advisory rather than prescriptive.
Any ethical involvement with the MDT meeting should be ﬁrst concerned with obtaining appro-
priate clinical facts that are founded on the best available evidence. These include
(1) the nature of the condition;
(2) its clinical effect on children, young people and parents;
(3) the associated clinical and psychosocial co-morbidities and their likely short- and long-term
consequences; and
(4) the ‘reversibility’ of treatment options (e.g., hormone suppression vs. gonadectomy; neonatal vs.
adolescent surgery).
Best interests
Although clinicians have a duty to act in the best interests of their patients30,objective standards of
best interests for children may be hard to deﬁne in isolation. In DSD, there may be tensions between
the potentially conﬂicting obligations of respecting a child or young person’s right to make informed
voluntary self-determined choices (autonomy) and providing treatment for the child that carries more
beneﬁt than harm. Moreover, any consideration of a child’s best interests needs to include the
obligation to respect the family and parent–child relationships.31,32
C.E. Brain et al. / Best Practice & Research Clinical Endocrinology & Metabolism 24 (2010) 335–354 347Traditional guidance for the timing and nature of therapeutic interventions in DSD may pay
insufﬁcient respect to the growing autonomy of adolescents and be overly paternalistic in its impact, or
may restrict future life choices. The adverse effects of failing to respect the developing autonomy of
adolescents are increasingly acknowledged.33,34
Dispute resolution
The structured format of the MDTmeeting may be a useful forum for dispute resolution, provided if
it has access to appropriate ethical expertise and knowledge of appropriate professional guidance and
protocols as well as relevant legal principles.
Good ethical decision making requires that the process of decision making be as transparent,
inclusive, reasonable and as accountable as possible. A practical approach to ethical decision making in
facilitated MDT meetings with ethical input is outlined in Table 3.35Other members
Other health-care professionals, who may be involved in the DSD MDT, include specialists in
radiology/imaging and histopathology (Fig. 1). Their attendance at meetings to discuss speciﬁc cases
can be invaluable. Specialists in reproductive medicine may contribute to discussions about complex
ethical and practical fertility issues and nurse specialists are in an ideal position to coordinate the team
and provide a link with families. Academic input can be important if there are individuals associated
with the team who have research interests in psychology, surgery, genetics or endocrinology.
The input of the local team can be extremely valuable. Parents often express their concerns,
preconceptions and desires at an early stage but these might get overlooked in the diagnostic process;
the local teammay have insight into these issues. The primary-care doctor/general practitioner is often
poorly informed about events, but may be an important source of support for the family and might
reﬂect upon the situation in a less medicalised environment. Finally, local community or religious
leaders can be very important in providing guidance in relation to personal religious doctrine, as well
as providing ongoing support over time.
The MDT meeting
The MDT meeting is an important forum during which the members of the team can gather and
discuss relevant cases. The exact structure and organisation of the meeting will vary between centres,
but in London we hold an MDT meeting to discuss newborn/paediatric cases once a month and
a separate MDTmeeting to discuss transition/adolescent/adult cases once every 2 or 3 months. If there
is an urgent need for keymembers of the team tomeet at other times, then this is arranged on an ad hoc
basis, and discussions between team members occur on an ongoing basis throughout the month. The
main MDT meeting is held in a room separate from the consultation room. This enables a broadTable 3
A practical approach to ethical decision making (adapted from UKCEN materials35).
MDT meetings with ethical input should address the following
Ascertain relevant clinical & psychosocial facts
Separate facts from values of those involved- professionals and family
Deﬁne an appropriate decision-making process e.g by determining
who has responsibility?
Who’s involved in the process? What is the status of each?
What is the time frame in which decision needs to be made?
List options for action and their morally signiﬁcant features e.g best interests, fairness
Ascertain what legal or professional guidance exists
Identify moral arguments for and against the options listed
Choose an appropriate treatment option
Identify the strongest ethical argument against its use, can it be rebuffed? Why?
Make a choice
Review outcomes and learn from experience
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having their privacy invaded. However, the family should be aware of the structure of the meeting and
not be made to feel excluded.
The MDT meeting provides an opportunity to
(1) review the clinical, cytogenetic, biochemical/endocrine, surgical and psychological ﬁndings for
challenging cases where a sex assignment is still pending and to discuss the team’s views or need
for further investigation with the parents at the time;
(2) review recent data on cases where sex assignment has beenmade, but to obtain the team’s opinion
on diagnosis, management and counselling;
(3) review any new or updated information available on cases that have been discussed in the past
(e.g., results of endocrine tests, ﬁndings at examination under anaesthesia (EUA), histology or
feedback from psychologists following further discussions with the family);
(4) plan any speciﬁc investigations for childrenwho may be coming into hospital soon (e.g., obtaining
speciﬁc samples at surgery or liaising with histopathology/cytogenetics about speciﬁc tests); and
(5) have detailed discussions involving ethicists and other specialists (e.g., reproductivemedicine) when
key questions arise in relation to a complex case (e.g., sex reassignment and cryopreservation).
The MDTmeeting brings together a large number of teammembers, as well as doctors, pathologists
and psychologists in training, experts in key areas from other centres and the local team. It is essential
to know everyone’s identity, and that they have undergone approval to attend. A teaching session or
journal review is often incorporated into the meeting, which forms part of ongoing education. An
overview of the range of cases observed or discussed at the Great Ormond Street Hospital MDTmeeting
over 26 months (24 meetings) is shown in Table 4.
Structure of the meeting
The MDT meeting at Great Ormond Street Hospital has been running for almost 20 years and the
adolescent meeting for almost 10 years. During this time, the meeting has undergone various changes
in format, which have been inﬂuenced by changes in the needs of parents and the team as well as
changes in the environment. It is important that the discussion room is sufﬁciently soundproofed to
avoid personal details being heard outside by others, and that any presentations or sensitive images
should not be seen outside the venue (e.g., blinds drawn). It is important to let any parents attending
the clinic know the structure of the clinic, likely time course and who they are likely to meet. Having
some familiar faces is always reassuring, which is why the involvement of the local team is important if
it is the family’s ﬁrst visit to the specialist centre.
Organisation
Originally, the DSD clinic was held in a single large room with a video link to a smaller consulting
room. This approach allowed the team to discuss details initially; then, only those keymembers involved
in the case would need to have direct contact with the baby and family. With the parents’ consent, the
video link allowed the urologists’ examination to be seen by the rest of the teamwithout a large number
of people being present. One disadvantage of this approach, however, was that only limited time was
available to spendwith the family; therefore, in recent years, we have adopted a largely discussion-based
approach to the clinic and try to see families at the start or at the end of themainmeeting.We usually see
one or two families each meeting and are able to discuss three to ﬁve other cases. The normal length of
the meeting is around 2.5–3 h, including a teaching session of 45 min. Increasingly complex cases have
been reviewed in recent years and cases are often discussed on multiple occasions.
Presentation, images, examination and governance
Case histories and data are usually presented in PowerPoint format from a secure hospital server.
Unnecessary personal details or speculative comments should be avoided and biochemical and
Table 4
Overview of the Great Ormond Street Hospital DSD meeting over approximately two years.
Sex Chromosome DSD (n¼ 13) 46,XY DSD (n¼ 65) 46,XX DSD (n¼ 23)
A: 47,XXY (Klinefelter Syndrome & variants) (2)
B: 45,X (Turner Syndrome & variants) (2)
(both Y fragment)
C: 45,X/46,XY mosaicism (mixed gonadal
dysgenesis & variants) (8)
D: 46,XX/46,XY (chimerism/mosaicism) (1)
A: Disorders of gonadal (testis) development
1. Complete gonadal dysgenesis (7)
2. Partial gonadal dysgenesis (8)
3. Steroidogenic factor-1 (2)
A: Disorders of gonadal (ovary) development
1. Ovotesticular DSD (1)
2. Testicular DSD (1)
B: Disorders in androgen synthesis or action
1. Disorders of androgen biosynthesis
STAR (1)
17b-HSD III (2)
5a-reductase II (6)
2. Disorders of androgen action
CAIS (6)
‘‘PAIS’’ (5)
B: Androgen excess
1. Fetal
21-hydroxylase (8)
11b-hydroxylase (2)
2. Fetoplacental
3. Maternal
C: Other
1. Syndromic associations of male genital development (11)
(e.g. chromosomal variants, skeletal, lung, skin, gastrointestinal,
Cornelia de Lange, CHARGE)
2. Cloacal anomalies (1)
3. IUGR/preterm/hypospadias (4)
4. Persistent Mu¨llerian duct syndrome (3)
5. Vanishing testis syndrome (2)
6. Isolated severe hypospadias (4)
7. Micropenis (1)
8. Bilateral undescended testes (2)
C: Other
1. Syndromic associations
(e.g. cloacal anomalies) (1)
2. Mu¨llerian agenesis (1)
3. Clitoromegaly, possible clitoromegaly or
clitoral variants (8)
4. Ovarian cysts (1)
Figures in bold (parentheses) show the current working diagnosis for individual cases seen or discussed during the DSD clinic over a 26month period (24multidisciplinary meetings). A total
of 101 different cases were discussed and, in addition, 42 repeat discussions, reviews or updates took place. Therefore, 143 cases were considered during this time period (average:
approximately 6 discussions per meeting). One case needed detailed input from ethicists. Of note, most cases of milder CAH or severe penoscrotal hypopadias weremanaged by the urology/
endocrinology/psychology teams without referral to the joint MDT meeting.
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presentation is usually put into the clinical notes as part of the medical record and electronic copies
kept on a secure server in keeping with local data-protection policies. In some countries, individuals
have the right to access all data held that concern them. This is in keeping with our policies of
encouraging transparency and disclosure in relation to DSD. Other standard guidelines for medical
conﬁdentiality should be adhered to.36
Photographic or video images can be useful for the MDT to review, and can also be an important
record for individuals and their parents later in life. Still photography should be viewedwith caution as,
for example, corporal size or consistency might not be apparent in a baby with suprapubic fat.
Concurrent documentation from an experienced examiner (ideally an urologist) to accompany the
photograph is needed. Video imaging of examination can be useful in some cases, and videos taken
during surgical laparoscopy can be invaluable for reviewing internal structures. Any photography of
external structures should be undertaken with full parental consent and ideally, only during anaes-
thesia in the older child. Images should be stored securely. Similarly, the examination should only be
conducted in an appropriate environment and undertaken by the relevant team member. Genital
examination should be limited to the minimal necessary in the older child and any detailed or invasive
examination that might be necessary undertaken under short general anaesthetic.
Discussions, documentation and databases
One of the most important features of the MDT meeting is to have an informed and balanced
discussion of cases with the child’s well-being as the central focus. Every case should be viewed on an
individual basis, as social and psychological perceptions vary between families, and a spectrum of
phenotypes can occur even for the same diagnosis. A literature review before themeeting is needed for
rare conditions or unusual ﬁndings and, as far as possible, evidence-based approaches to decision
making should be adopted.
The MDT meeting offers a unique forum for interactive discussion, review and contemplation. The
MDT ‘consensus’ can give invaluable support to those key team members dealing directly with the
families, can allow balanced review of data/diagnosis and can help to formulate a joint plan for future
investigation and management. It is also important to question decisions and opinions by offering an
opposing view. This can ensure that all options are well thought out, that the outcome of the
discussions truly reﬂects consensus opinion and that advocacy for the child is provided within the
context of the family. Sometimes, discussion with an ethicist or ethics committee is needed to try to
resolve conﬂict of opinionwithin the team, or when decisions are extremely difﬁcult (e.g., discordance
between the parents’ views and the recommendation of the MDT; see above).
Documenting the results of the discussions and management plan in the medical records and
communicating these with the parents and relevant health-care professionals are important. It is often
easy to overlook local services, who may offer invaluable support to the family. However, sensitive
information should be disseminated on a ‘need to know’ basis, and ideally with the family’s consent.
Local databases can be very useful for helping organise data on individuals being discussed at the
MDT meeting and coordinating future plans. As noted above, any such databases should comply with
local data-protection policies. Audit of local services might be useful and seeking feedback from
parents, children/young people and adults attending the meetings and clinics is important to try to
improve the ‘patient journey’.With changes in policy and practice, it is likely that anMDTmeeting such
as this will continue to evolve in the future.
Follow-up in childhood
It is essential that all infants are followed up both in the short and long term to be able to monitor
growth, assess the outcomes of surgery and to facilitate transition at the appropriate time.
During this process, it is important not to ‘medicalise’ the follow-up protocol for the child/young
person, and we tend to minimise physical and, in particular, genital inspection.
It is important that there is a key physician and surgeon involved who will ideally follow the child
through to adolescence with appropriate input from psychology. The psychologist will be closely
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planning of puberty and transition to the adolescent DSD service.
Facilitating the collection of long-term outcome data is essential to be able to provide feedback and
positively inﬂuence early management decisions such as the need for, and timing of, genital surgery.
Transition
There is little speciﬁc information on transition from paediatric to adult services for children
with DSD. However, the general principles of transition are the same as for any chronic medical
condition. Many of these are covered in the documents produced by the Department of Health.37,38
Generic issues include accessibility and co-location where possible of services, staff training,
conﬁdentiality and consent and health promotion. Young patients need to be encouraged to
engage with services themselves and take a greater role in planning their own treatments.
Adolescence is a time of uncertainty for all young people with the development of sexual identity
and worries about relationships. These concerns are likely to be much greater in the presence of
the diagnosis of a DSD. Understanding and coming to terms with an unusual karyotype or the
requirement for further reconstructive genital surgery is a daunting prospect and specialised
psychological input is crucial.
It would seem logical that the model of multidisciplinary care is just as appropriate for adolescents
as it is for children. The involvement of both paediatric and adult clinicians can allow for careful
transfer of information and strategic planning for the future. Speciﬁc milestones during transition are
disclosure of diagnosis and genital assessment. The timing of disclosure varies hugely between patients
and may be complete early in adolescence or not until the late teenage years. Either may be appro-
priate, but it is essential that there is close communication between clinicians involved in the progress.
Girls usually require vaginal assessment at some stage during adolescence. In the presence of
a uterus, assessmentmay be required to conﬁrm there is a passageway beforemenstruation starts. This
is usually done under a brief general anaesthetic. In the absence of a uterus, the vaginal examination
can be deferred until the girl is contemplating sexual activity and is usually performed in the outpatient
clinic.
If vaginal dilation is required, success rates are good but are directly related to compliance. Support
from a psychologist and supervision from a dedicated clinical nurse specialist are important. This
usually provides an opportunity to explore worries about current and potential sexual relationships.
Long-term outcome data
There is a general paucity of long-term outcome data for this group of patients as awhole, bothmale
and female.10 Many adults with DSD have been lost to follow-up and historically this may, at least in
part, have been due to insensitive or inappropriate care by clinicians. Delayed or even non-disclosure of
the diagnosis was standard medical practice until relatively recently.13 As a result, it has often been
difﬁcult (both practically and ethically) to recruit into follow-up studies older patients whomay not be
aware of their karyotype. In addition, the original diagnoses may be incomplete or even incorrect.39
More recently, however, the advent of well-organised and better-informed patient peer-support
groups, together with easy Internet access, has led to increasing numbers of older adult patients
seeking information on every aspect of their condition. This should in turn increase our store of
knowledge when advising younger patients, particularly as they approach adolescence.
It is essential that we plan a seamless pathway of transition, from paediatric through adolescent and
into adult services. This will not only serve to optimise the care of individuals with DSD, but it will also
ensure that both short- and long-term outcome data are collected and translated into better future
management strategies.
Summary
We believe that a holistic, multidisciplinary approach is mandatory for patients presenting with
DSD. Input from a variety of health professionals facilitates rapid and effective assessment and
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provides the families with immediate support and coping strategies. The development of audit and
research is also facilitated through the collaboration of the various health professionals involved
with these patients. A recent survey of key paediatric endocrinology centres in Europe reported an
MDT dealing with DSD was established in the majority of those centres that responded.40 Whilst this
is encouraging, the experience and training of team members may be variable and it is likely that
services for young people and adults with DSD are less well established. The facilitation of adolescent
transition and long-term follow-up by adult focussed MDTs will help to improve the future
management of these conditions with a view to optimising the provision of health services for DSD
and related conditions across the life span. Appropriate training, education and funding is needed if
this goal is to be achieved.Practice points
 Individuals with DSD should have access to an MDT with experience in the diagnosis and
management of these conditions.
 An experienced psychologist plays a central role in the management of DSD across the life
span.
 Although achieving an early diagnosis can help with management decisions and counselling,
an individualised approach is needed in every case.
 Proper transition of young people to adolescent and adult services is essential, as is the
establishment of adult DSD services based on an MDT model.
Research agenda
 Better understanding of the basic mechanisms of sex development is needed to improve
diagnosis and to evaluate the biological effects of speciﬁc genes, proteins, hormones and
environmental or epigenetic events.
 Improved biomarkers, imaging technologies and psychological tools are needed to assess
gonadal function, androgen exposure/action, early tumour risk, reproductive potential and
gender identity within the MDT setting.
 Further research is needed into optimal disclosure strategies and how best to transition care
for young people with DSD into adult services.
 Good-quality long-term outcome studies are needed to evaluate the advantages and risks of
intervention (surgical, psychological and hormonal) and to optimise strategies for tumour-
risk management, fertility potential, sexual function, hormone replacement, bone health
and quality of life.
 Better strategies are needed to educate health-care practitioners, patients and families and
the general public about sex development, reproductive function and DSD.Acknowledgements
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